Teyi Pharmaceutical Group's low P/E ratio is seen as reasonable given its expected underperformance and shrinking earnings outlook. Shareholders accept this, anticipating no pleasant surprises in future earnings. A strong share price rise seems unlikely under these conditions.

Despite a recent share price drop, the company's strong past performance may present an investment opportunity. However, market expectations for growth seem moderated. The company's total shareholder return, including dividends, has been impressive, boosting overall returns.

Teyi Pharmaceutical GroupLtd's financial inconsistencies call for caution despite high ROE. Low earnings growth & high payout ratio hint poor capital allocation & risk, signaling an unclear future growth outlook.